Increased Mortality in SDHB but Not in SDHD Pathogenic Variant Carriers by Rijken, Johannes A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/201148
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
cancers
Article
Increased Mortality in SDHB but Not in SDHD
Pathogenic Variant Carriers
Johannes A. Rijken 1,* , Leonie T. van Hulsteijn 2, Olaf M. Dekkers 2,3,
Nicolasine D. Niemeijer 2, C. René Leemans 1, Karin Eijkelenkamp 4,
Anouk N.A. van der Horst-Schrivers 4, Michiel N. Kerstens 4, Anouk van Berkel 5,
Henri J.L.M. Timmers 5, Henricus P.M. Kunst 6, Peter H.L.T. Bisschop 7, Koen M.A. Dreijerink 8,9,
Marieke F. van Dooren 10, Frederik J. Hes 11 , Jeroen C. Jansen 12, Eleonora P.M. Corssmit 2 and
Erik F. Hensen 1,12
1 Department of Otolaryngology/Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam,
De Boelelaan 1117, 1081 HZ Amsterdam, The Netherlands; cr.leemans@vumc.nl (C.R.L.);
E.F.Hensen@lumc.nl (E.F.H.)
2 Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, 2333 ZA Leiden,
The Netherlands; lvanhulsteijn@hotmail.com (L.T.v.H.); O.M.Dekkers@lumc.nl (O.M.D.);
nniemeijer@ysl.nl (N.D.N.); E.P.M.van_der_Kleij-Corssmit@lumc.nl (E.P.M.C.)
3 Departments of Epidemiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
4 Department of Endocrinology, University Medical Center Groningen, University of Groningen, Hanzeplein
1, 9713 GZ Groningen, The Netherlands; k.eijkelenkamp@umcg.nl (K.E.);
a.n.a.van.der.horst@umcg.nl (A.N.A.v.d.H.-S.); m.n.kerstens@umcg.nl (M.N.K.)
5 Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center,
Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands; anouk.vanberkel@radboudumc.nl (A.v.B.);
henri.timmers@radboudumc.nl (H.J.L.M.T.)
6 Department of Otolaryngology/Head and Neck Surgery, Radboud University Medical Center, Geert
Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands; dirk.kunst@radboudumc.nl
7 Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Meibergdreef
9, 1105 AZ Amsterdam, The Netherlands; p.h.bisschop@amc.uva.nl
8 Department of Endocrinology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht,
The Netherlands; k.dreijerink@vumc.nl
9 Department of Endocrinology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HZ
Amsterdam, The Netherlands
10 Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Doctor
Molewaterplein 40, 3015 GD Rotterdam, The Netherlands; m.vandooren@erasmusmc.nl
11 Department of Clinical Genetics, Leiden University Medical Center, De Boelelaan 1117, 1081 HZ Leiden,
The Netherlands; F.J.Hes@lumc.nl
12 Department of Otolaryngology/Head and Neck Surgery, Leiden University Medical Center, Albinusdreef 2,
2333 ZA Leiden, The Netherlands; j.c.jansen@lumc.nl
* Correspondence: j.rijken@vumc.nl; Tel.: +31-204443690; Fax: +31-204440314
Received: 17 December 2018; Accepted: 13 January 2019; Published: 17 January 2019


Abstract: Germline mutations in succinate dehydrogenase subunit B and D (SDHB and SDHD) are
predisposed to hereditary paraganglioma (PGL) and pheochromocytoma (PHEO). The phenotype of
pathogenic variants varies according to the causative gene. In this retrospective study, we estimate
the mortality of a nationwide cohort of SDHB variant carriers and that of a large cohort of SDHD
variant carriers and compare it to the mortality of a matched cohort of the general Dutch population.
A total of 192 SDHB variant carriers and 232 SDHD variant carriers were included in this study.
The Standard Mortality Ratio (SMR) for SDHB mutation carriers was 1.89, increasing to 2.88 in carriers
affected by PGL. For SDHD variant carriers the SMR was 0.93 and 1.06 in affected carriers. Compared
to the general population, mortality seems to be increased in SDHB variant carriers, especially in
those affected by PGL. In SDHD variant carriers, the mortality is comparable to that of the general
Cancers 2019, 11, 103; doi:10.3390/cancers11010103 www.mdpi.com/journal/cancers
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Dutch population, even if they are affected by PGL. This insight emphasizes the significance of
DNA-testing in all PGL and PHEO patients, since different clinical risks may warrant gene-specific
management strategies.
Keywords: SDHB; SDHD; mortality; paraganglioma; pheochromocytoma
1. Introduction
Paragangliomas (PGL) are rare tumors that originate from cells of neural crest origin in the
paraganglia associated with the autonomic nervous system. PGL can be subdivided into head
and neck paragangliomas (HNPGL), pheochromocytomas (PHEO), and thoracic and abdominal
extra-adrenal PGL (sympathetic PGL; sPGL). An increasing number of genes are associated with
hereditary PGL/PHEO. Most frequently, hereditary PGL syndrome is caused by genes encoding
subunits or cofactors of succinate dehydrogenase (SDH), such as SDHA/B/C/D/AF2. Other associated
genes are RET, NF1, VHL, HIF2A, FH, TMEM127, and MAX [1,2]. In the Netherlands, pathogenic
variants in SDHD are the most prevalent cause of PGL syndrome, followed by variants in SDHB and
SDHA [3,4]. Although all SDHx genes encode subunits of the same SDH complex and pathogenic
variants all disrupt its enzymatic function, different genes are associated with different phenotypes.
The reported lifelong penetrance of pathogenic SDHB variants (22–42%) [5,6] is considerably lower
than the penetrance of paternally inherited SDHD mutations (88–100%) [7–10].
When pathogenic SDHB variants cause disease, the clinical outcome is reported to be less favorable
than that in SDHD-linked disease. SDHB mutation carriers are reported to develop metastatic PGL
more frequently and patients with metastatic disease associated with SDHB variants are reported to
have a poor 5-year survival rate compared to patients with metastatic disease associated with other
causative genes [11]. The mortality of SDHB variant carriers is currently unknown [12]. In this study
we estimate the mortality for a nationwide cohort of SDHB variant carriers and compare this risk with
the mortality of SDHD variant carriers and that of the general Dutch population.
2. Subjects and Methods
2.1. Eligibility Criteria
The cohort of pathogenic germline variant carriers (hereafter variants) in SDHB included in this
study has been described in detail previously [6,13]. The mortality of this nationwide SDHB-linked
cohort was compared with the mortality of the general Dutch population and with the mortality of
an updated cohort of SDHD variant carriers, which has been described previously [12]. Only SDHD
variant carriers with paternal inheritance were included. Carriers of SDHD variants were identified
using the database of the Laboratory for Diagnostic Genome Analysis (LDGA) at the Leiden University
Medical Center (LUMC), a tertiary referral center for patients with PGL. Screening for SDH variants
was performed in all persons diagnosed with PGL who agreed to genetic testing.
Screening for SDHB and SDHD variants was performed by direct sequencing of peripheral blood
leucocytes using the Sanger method on an ABI 377 Genetic Analyzer (Applied Biosystems, Carlsbad,
California) and by multiplex ligation-dependent probe amplification (MLPA) using the P226 MLPA
kit (MRC Holland, Amsterdam, the Netherlands). Family members of index patients were tested for
the family-specific variant. All variants described in this study were submitted to the Leiden Open
(source) Variation Database LOVD database (http://chromium.liacs.nl/lovd_sdh). SDHB and SDHD
germline variants were classified according to the international guidelines put forth by Plon et al. [14].
SDHD variants were described using the reference sequence NG_012340.1 covering SDHB transcript
NM_003000.2, and NG_012337.1 covering SDHD transcript NM_003002.2, available from the TCA
Cycle Gene Variant Database LOVD database. In this manuscript we report pathogenic or likely
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pathogenic variants, including missense mutations in highly conserved regions that are determined to
be likely pathogenic as germline mutations based partly on mutation prediction analyses. Information
on amino acid conservation can be found in the LOVD database (http://chromium.liacs.nl/lovd_sdh).
Further information including mutation prediction analyses can be obtained on request.
The study was approved by the Medical Ethics Committee of the Leiden University Medical
Center; participating centers complied with their local Medical Ethics Committee requirements. Written
informed consent was obtained from the parents/guardians of individuals under 18 years of age.
2.2. Clinical Characteristics
Clinical data were retrieved from medical records. Pathogenic variant carriers were investigated
for occurrences of PGL and/or PHEO according to the structured protocols used for standard care
in the Netherlands for PGL or PHEO patients [15,16]. Patients were offered clinical surveillance
for PGL/PHEO at the departments of otorhinolaryngology and endocrinology. For asymptomatic
SDHB and SDHD variant carriers older than 18 years of age, surveillance consisted of magnetic
resonance imaging (MRI) of the head and neck region once every 2–3 years, and MRI or computed
tomography (CT) scans of the thorax, abdomen, and pelvis once every 1–2 years in SDHB variant
carriers. Biochemical screening was performed annually on SDHB variant carriers, and every 1–2
years on SDHD variant carriers. This screening measured levels of (nor)epinephrine, vanillylmandelic
acid, dopamine, (nor)metanephrine, and/or 3-methoxytyramine in two 24-hour urinary samples
(depending on the Academic Center in which urinary measurement(s) were performed), and/or
plasma free (nor)metanephrine and 3-methoxytyramine. In cases of excessive catecholamine
secretion (i.e., any value above the upper reference limit), radiological assessment by MRI or
CT scans of the thorax, abdomen, and pelvis, and/or 123I metaiodobenzylguanidine (MIBG)
scans, positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG PET)
scans, 18F-L-dihydroxyphenylalanine (18F-DOPA) PET-scans, or positron emission tomography
with 1,4,7,10-tetraazacyclododecane-NI, NII, NIII, NIIII-tetraacetic acid (D)-Phe1-thy3-octreotide
(68Ga-DOTATOC PET) scans were performed to identify potential sources of excessive catecholamine
production. In cases without available tumor histology, tumors were classified as paraganglionic based
on their specific characteristics in CT and/or MRI scans. When in doubt, additional nuclear medicine
imaging studies were performed in order to confirm the diagnosis. At the time of this study, there were
no national, structured protocols for surveillance in SDHB mutation carriers younger than 18 years of
age. Therefore, the method and interval of surveillance in this age category varied between centers.
In case of a diagnosis of HNPGL, PHEO or sPGL, intensified surveillance or treatment was offered.
Surgical resection was generally the preferred treatment option for PHEO or sPGL. In cases of HNPGL,
the management strategy was guided by clinical symptoms, tumor characteristics such as localization,
size, and growth rate, and patient characteristics such as age, comorbidity, and patient preferences.
A wait and scan policy, radiotherapy, or surgical resection were possible treatment options.
2.3. Mortality and Survival
For this study, follow-up data from SDHB and SDHD variant carriers were included from the date
of the DNA test. In cases where clinical follow-up was available for the period before the DNA test,
this period was not considered in the mortality analysis because it would have introduced immortal
time bias [17]. Follow-up was defined as the time between the DNA test and the last clinical follow-up
date before the end of the study period. Patients who were alive at the last clinical follow-up were
classified as alive. Follow-up ended at the end of the study period, at the date of death or, in case of
emigration, at the date of emigration [13]. To compare mortality between SDHB and SDHD variant
carriers and the general population, the standardized mortality ratio (SMR) was estimated. Mortality
rates for the Dutch population were obtained from Statistics Netherlands (CBS, The Netherlands) [18],
using rates stratified by sex, age (per 1 year) and date (1-year periods). The SMR was calculated
by dividing the observed number of deaths in the SDHB and SDHD cohorts. The expected number
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of deaths was calculated as the sum of the stratified number of expected deaths (stratum-specific
mortality rates from the general population times follow-up time at risk).
Survival was graphically displayed for SDHB and SDHD variant carriers by plotting survival in
the carriers against the expected survival based on matched data from the general population. STATA
14.0 (Stata Corp, Texas, USA) was used for statistical analysis.
3. Results
In total, 192 SDHB variant carriers and 232 SDHD variant carriers were included in this study.
The clinical characteristics are depicted in Table 1. The mean age at identification of the pathogenic
gene variant was 46 years (range 9–77) in SDHB variant carriers and 44 years (range 16–73) in SDHD
variant carriers. In total, 53 SDHB variant carriers (27.6%) and 198 SDHD variant carriers (85.3%)
were diagnosed with HNPGL, either at time of presentation or during follow-up. Four SDHB patients
(2.1%) and 16 SDHD patients (6.9%) developed PHEO and 26 SDHB patients (13.5%) and 18 (7.8%)
SDHD patients developed sPGL. Malignant PGL, defined as metastatic PGL in non-paraganglionic
tissue, were diagnosed in 14 SDHB (7.3%) and four SDHD patients (1.7%). Most SDHB variant carriers
(110/193; 57.3%) were not affected at the time of DNA testing or during follow-up. In contrast,
the majority of SDHD variant carriers was diagnosed with SDHD-associated disease (203/232; 87.5%).
Details of the specific SDHB and SDHD variants are included in Appendix A.
Table 1. Clinical characteristics of carriers of pathogenic variants in succinate dehydrogenase subunits
B and D (SDHB and SDHD).
Clinical Characteristics
SDHB
n = 192
SDHD
n = 232
Male (%)/female (%) 81 (42.2)/111 (57.8) 123 (53.0)/109 (47.0)
Mean age at genetic testing 46 years (range 9–77) 44 years (range 16–73)
HNPGL (%) 53 (27.6) 198 (85.3)
sPGL (%) 26 (13.5) 18 (7.8)
Pheochromocytoma (%) 4 (2.1) 16 (6.9)
Malignant PGL (%) 14 (7.3) 4 (1.7)
Unaffected (%) 110 (57.3) 30 (12.9)
HNPGL = head and neck paraganglioma, sPGL = sympathetic paraganglioma, PGL = paraganglioma.
Mortality and SMR
Mortality data were available for all SDHB and SDHD variant carriers. The mean follow-up
period was 3.0 (range 0–14.5) and 5.1 (range 0–12.5) years, respectively, for SDHB and SDHD variant
carriers. In total, 6/192 (3.1%) SDHB variant carriers died at age 32, 37, 49, 52, 62, and 63. In three
patients the cause of death was directly related to progressive PGL disease. In contrast, 5/232 (2.2%)
SDHD variant carriers died at age 41, 43, 71, 71, and 74. In two cases the cause of death was most likely
associated with PGL disease. Clinical characteristics of the variant carriers who died during the study
period are listed in Table 2.
A direct comparison between SDHB and SDHD variant carriers is hampered by the limited
number of carriers and the heterogeneity between both groups. We performed an adjusted Poisson
regression, adjusting for age, sex, and calendar time. The rate ratio comparing SDHB to SDHD variant
carriers was 0.48 (95% confidence interval (CI) 0.15–1.62). However, the power for this analysis is low.
As both groups have few events, we cannot draw conclusions from the non-significant p-value.
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Table 2. Details of six SDHB and five SDHD variant carriers who died during follow-up.
Sex Mutation PredictedProtein Change Location of PGL
Age at PGL
Diagnosis
(years)
Age at Diagnosis
of Malignant
Disease (years)
Age at
Death
(years)
Location of
Metastases Cause of Death
M SDHBexon 3 deletion p.? Presacral 28 28 32 Bone Progressive malignant PGL
F SDHBc.654G > A p.(Trp218*) Bladder 19 58 62 Lymph nodes, bone Progressive malignant PGL
F SDHBexon 3 deletion p.?
Para-vertebral
abdominal 33 33 37 Lymph nodes, bone Progressive malignant PGL
F SDHBc.727T > A p.(Cys243Ser)
Retroperitoneal
(para-aortic) 52 55 63 Bone
Myocardial infarction, heart
failure and acute respiratory
distress syndrome
F SDHBc.423 + 1G > A p.? n.a. 49 n.a. 52 n.a.
Respiratory insufficiency due to
lung bleeding after
chemoradiotherapy for lung
cancer
F SDHBc.423 + 1G > A p.? n.a. 42 n.a. 49 n.a. Metastatic breast cancer
F SDHDc.274G > T p.(Asp92Tyr) Bladder 42 42 43
Lymph nodes, bone
marrow Progressive malignant PGL
F SDHDc.274G > T p.(Asp92Tyr) Mediastinal 67 67 74 Lymph nodes, bone
Unknown, however the patient
was known to have progressive
malignant PGL
F SDHDc.274G > T p.(Asp92Tyr) Bilateral CBT, VBT 55 n.a. 71 n.a. Cardiac arrest
F SDHDc.242C > T p.(Pro81Leu) CBT 38 n.a. 41 n.a. Breast cancer
M SDHDc.274G > T p.(Asp92Tyr)
CBT, jugular PGL,
retroperitoneal 52 n.a. 71 n.a. Prostate cancer
PGL = paraganglioma, CBT = carotid body tumor, VBT = vagal body tumor, n.a. = not applicable.
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For the comparison of both the SDHB- and SDHD-linked cohorts with normative data of the
Dutch population, a total of 1781 person-years were available (SDHB 590 and SDHD 1191 years,
respectively). The SMR for SDHB mutation carriers was 1.89 (95% confidence interval (CI) 0.85–4.21)
(Figure 1). A separate analysis including only symptomatic SDHB variant carriers—i.e., those with
manifest disease—showed a higher SMR at 2.88 (95% CI 1.08–7.68). These results suggest an increased
mortality risk for SDHB variant carriers compared to the general Dutch population, especially for
carriers affected by SDHB-associated disease. For SDHD variant carriers, the SMR was 0.93 (95%
CI 0.39–2.23), increasing only slightly to 1.06 (95% CI 0.44–2.54) in affected carriers, suggesting that
mortality is not increased in SDHD variant carriers.
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4. Discussion
In this study we estimated the mortality for SDHB and SDHD pathogenic variant carriers. Whereas
the mortality for SDHD variant carriers is comparable with a matched cohort of the general Dutch
population (SMR = 0.93), SDHB variant carriers show a higher mortality (SMR = 1.89, meaning a 1.89
times higher risk of death than the matched cohort of the general Dutch population).
These mortality ratios should be interpreted with some caution. First, not all deaths in our cohort
are directly attributable to PGL-linked disease. However, a comparison is made with the mortality of
the general Dutch population. Therefore, eliminating other causes of death would be inappropriate.
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Second, even though the SDHB variant carriers represent a nationwide cohort, PGL is a rare
disease and patient numbers are inevitably limited. As a result, the study estimates have broad
confidence intervals. In addition, the follow-up of the start of this study is defined as the time of DNA
testing and not PGL/PHEO diagnosis. As the genetic causes of hereditary PGL syndromes have been
determined only recently, follow-up is relatively limited. However, the differences between SDHB
and SDHD variant carriers are remarkable, all the more so when considering that SDHD variants are
characterized by a high penetrance of PGL (88–100%), and SDHB variants by a much lower lifelong
PGL risk (22–42%) [5–10]. In SDHD variant carriers, the occurrence of often multiple associated
(HN)PGL seems to have no clear impact on survival [12]. In contrast, SDHB variant carriers seem to
face increased mortality even though they are under more intensive surveillance and, in our study,
have a shorter follow-up. This decreased survival of SDHB variant carriers is attributable to the higher
mortality of affected SDHB patients (SMR = 2.88). Moreover, the majority of deceased SDHB-linked
patients suffered from progressive malignant PGL (Table 2). Unaffected SDHB variant carriers have a
mortality ratio that is more in line with the general Dutch population (SMR = 1.12).
It is intriguing that the causative gene seems to determine variation in the prognoses for
PGL/PHEO patients, even though pathogenic variants in SDHB and SDHD cause PGL/PHEO
syndrome through defects in the same protein complex (succinate dehydrogenase, SDH). We speculate
that this could be the result of intrinsic properties of the SDHB-associated PGL/PHEO syndrome,
a deleterious effect of SDHB variants on other factors that influence survival, or differences between
SDHB and SDHD variants in the potential to induce other types of malignancy. Interestingly,
other types of malignancies (i.e. prostate cancer, lung cancer, breast cancer) are listed as causes
of death both in the SDHB- and SDHD-linked cohorts (see Table 2). Although the SDHx-associated
tumor spectrum is expanding, none of these malignancies have been directly linked to SDHB or SDHD
variants. Even so, SDHD and/or SDHB variants could alter the susceptibility to certain types of
malignancy other than PGL/PHEO. Indeed, 0.25% and 0.05% of breast cancer exomes carry somatic
SDHB and SDHD variants, respectively [19,20].
The finding that all deceased SDHB-related PGL patients had metastatic PGL suggests that the
occurrence of metastatic disease in SDHB-linked PGL syndrome particularly impacts survival, and that
metastases may be either more prevalent in SDHB-linked cases, as suggested before [7,10,21–24],
or more aggressive than metastatic diseases associated with other SDHx genes, a finding that is in line
with the very poor 5-year survival rate of SDHB-linked metastatic disease reported by Amar et al. [11].
Another explanation might be that metastases from sPGL behave more aggressively than those of
parasympathetic HNPGL, and that these sPGL are more prevalent in SDHB-linked disease [13,25].
Indeed, the PGL patients that died of progressive PGL disease both in the SDHB- and SDHD-linked
cohorts all suffered from primary sPGL tumors.
The difference in the mortality between SDHB and SDHD variant carriers is another clear
indication that causative genetic alteration is of critical importance to the outcome and risks of
an individual PGL patient. This is important in counseling PGL/PHEO patients, but may also warrant
gene-specific management strategies for PGL patients. In the present study, however, we did not
evaluate the effect of PGL follow-up protocols or treatment on survival. From the patients that died
of SDHB-related disease (n = 3), two already had proven metastatic disease at the time of diagnosis.
Surgical resection with tumor-free margins seems to be a logical treatment strategy when trying to
avoid progression of the disease, but there may be undetected metastases already present at the
time of surgery [26,27]. The observation that the higher mortality associated with SDHB variant
carriers seems to be attributable to patients that are affected by metastatic sPGL may warrant a more
aggressive surgical strategy towards sPGL tumors in SDHB-linked patients. The risk of the malignant
transformation of an sPGL tumor left untreated is, however, unknown. This unknown risk of disease
progression must be weighed against the risk of surgical morbidity [28].
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5. Conclusion
In conclusion, compared to a matched cohort of the general population, mortality is increased
in SDHB variant carriers but not in SDHD variant carriers. This insight emphasizes the significance
of DNA-testing; gene-specific clinical risks may warrant tailored management strategies. Further
research is necessary to demonstrate the effect of (early) intervention of PGL/PHEO on mortality rates,
especially in SDHB variant carriers.
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Appendix A. SDHB Variants and SDHD Variants
DNA Mutation Predicted Protein Change Number of Subjects (%)
Exon 3 deletion p.? 59 (30.7)
c.423 + 1G > A p.? 45 (23.4)
c.654G > A p.(Trp218*) 19 (9.9)
c.653G > C p.(Trp218Ser) 11 (5.7)
c.574T > C p.(Cys192Arg) 8 (4.2)
c.200 + 1G > A p.? 6 (3.1)
c.137G > A p.(Arg46Gln) 4 (2.1)
c.328A > C p.(Thr110Pro) 4 (2.1)
c.418G > T p.(Val140Phe) 4 (2.1)
c.725G > A p.(Arg242His) 3 (1.6)
c.649C > T p.(Arg217Cys) 3 (1.6)
c.590C > G p.(Pro197Arg) 3 (1.6)
c.686_725del p.(Glu229fs) 3 (1.6)
c.343C > T p.(Arg115*) 3 (1.6)
c.292T > C p.(Cys98Arg) 2 (1.0)
Deletion promoter and exon 1 p.? 1 (0.5)
Deletion promoter till exon 8 p.0 2 (1.0)
Exon 2 deletion p.? 2 (1.0)
Exon 1 deletion p.? 2 (1.0)
c.713delT p.(Phe238fs) 1 (0.5)
c.727T > A p.(Cys243Ser) 1 (0.5)
c.761C > T p.(Pro254Leu) 1 (0.5)
c.626C > T p.(Pro209Leu) 1 (0.5)
c.380T > C p.(Ile127Thr) 1 (0.5)
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DNA Mutation Predicted Protein Change Number of Subjects (%)
c.325A > C p.(Asn109His) 1 (0.5)
c.1A > G p.? 1 (0.5)
c.119A > C p.(Lys40Thr) 1 (0.5)
c.274G > T p.(Asp92Tyr) 175 (74.7)
c.416T > C p.(Leu139Pro) 34 (14.6)
c.284T > C p.(Leu95Pro) 6 (2.6)
Deletion promoter, exon 1 and 2 p.? 4 (1.7)
c.242C > T p.(Pro81Leu) 3 (1.3)
c.337_340delGACT p.(Asp113fs) 2 (0.9)
c.122dupC p.(Glu42fs) 2 (0.9)
Exon 1. c.3G > C p.(Met1Ile) 1 (0.4)
Exon 2: c.169_169 + 9del10, splice donor mutation p.? 1 (0.4)
Intron 2 c.169_169 + 9del p.? 1 (0.4)
Specific SDHD variant unknown (tested elsewhere) unknown 3 (1.3)
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